Home / Business and Economy / Argenx: Analysts See 40% Surge Ahead
Argenx: Analysts See 40% Surge Ahead
20 Sep
Summary
- Argenx shares have risen 30% in the last year.
- Company reported 18 consecutive quarters of revenue growth.
- Phase 3 Alkivia study showed positive results for Vyvgart Hytrulo.
Argenx (NASDAQ: ARGX) has demonstrated significant investor value, with its stock price appreciating approximately 30% over the last 12 months. Wall Street analysts maintain a bullish outlook, with a consensus price target suggesting a potential 20% upside, and two analysts forecasting over 40% growth in the coming year.
The company's financial performance has been robust, marked by 18 consecutive quarters of revenue expansion. In the second quarter of 2026, Argenx achieved an impressive 60% year-over-year sales increase, with revenue climbing 16% from the prior quarter. Earnings nearly doubled, soaring 93% year over year in the same period.
Pipeline advancements also contribute to the positive sentiment. On August 17, 2026, Argenx announced favorable outcomes from the late-stage Alkivia study for Vyvgart Hytrulo in autoimmune myositis. This marks a significant milestone as the first Phase 3 trial to demonstrate statistically significant improvement for immune-mediated necrotizing myopathy (IMNM), a condition lacking approved therapies.
While Argenx's growth prospects appear bright, potential risks include over-reliance on the Vyvgart franchise and upcoming clinical trial results for empraisprubart. Broader market downturns could also impact stock performance. Nevertheless, the company's consistent financial growth and proven success across multiple autoimmune diseases provide a strong foundation for future expansion.
